Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings

Cephalalgia

Volumn 35, Issue 3, 2015, Pages 271-284

  Orr, Serena L ^a,b   Aubé, Michel ^b   Becker, Werner J ^c   Davenport, W Jeptha ^d   Dilli, Esma ^e   Dodick, David ^f   Giammarco, Rose ^g   Gladstone, Jonathan ^h   Leroux, Elizabeth ⁱ   Pim, Heather ^j   Dickinson, Garth ^a   Christie, Suzanne N ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Mayo Clinic   (United States)

^h HAMILTON HEALTH SCIENCES   (Canada)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

acute pain; emergency; headache; management; Migraine

Indexed keywords

CHLORPROMAZINE; CLONIXIN LYSINE; DEXAMETHASONE; DICLOFENAC; DIHYDROERGOTAMINE; DROPERIDOL; ERGOTAMINE; GRANISETRON; HALOPERIDOL; KETOROLAC; LIDOCAINE; LYSINE ACETYLSALICYLATE; MAGNESIUM SULFATE; METOCLOPRAMIDE; MORPHINE; OCTREOTIDE; PARACETAMOL; PETHIDINE; PROCHLORPERAZINE; PROPOFOL; SUMATRIPTAN; TRAMADOL; TRIMETHOBENZAMIDE; VALPROIC ACID;

CANADA; DRUG INDICATION; EMERGENCY HEALTH SERVICE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL SOCIETY; MIGRAINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ANALGESIA; MIGRAINE DISORDERS; PRACTICE GUIDELINE; PROCEDURES; PROSPECTIVE STUDY; STANDARDS; TREATMENT OUTCOME;

CANADA; EMERGENCY MEDICAL SERVICES; HUMANS; MIGRAINE DISORDERS; PAIN MANAGEMENT; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84923920368     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102414535997     Document Type: Review

References (80)

1. Pryse-Phillips W, Findlay H, Tugwell P, et al. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992 ; 19: 333-339
2. O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: A population-based survey. Int J Epidemiol. 1994 ; 23: 1020-1026
3. Cooke L, Becker W. Migraine prevalence, treatment and impact: The Canadian Women and Migraine study. Can J Neurol Sci. 2010 ; 37: 580-587
4. Lipton RB, Liberman JN, Kolodner KB, et al. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. Cephalalgia. 2003 ; 23: 441-450
5. Jelinski SE, Becker WJ, Christie SN, et al. Demographics and clinical features of patients referred to headache specialists. Can J Neurol Sci. 2006 ; 33: 228-234
6. Brna P, Gordon K, Dooley J. Health-related quality of life among Canadians with migraine. J Headache Pain. 2007 ; 8: 43-48
7. Leonardi M, Raggi A, Ajovalasit D, et al. Functioning and disability in migraine. Disabil Rehabil. 2010 ; 32: S23 - S32
8. Raggi A, Leonardi M, Ajovalasit D, et al. Disability and functional profiles of patients with migraine measured with ICF classification. Int J Rehabil Res. 2010 ; 33: 225-231
9. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLD) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 ; 380: 2163-2196
10. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: The seventh disabler. Cephalalgia. 2013 ; 33: 289-290
11. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999 ; 159: 813-818
12. Edmeads J, Mackell JA. The economic impact of migraine: An analysis of direct and indirect costs. Headache. 2002 ; 42: 501-509
13. Lambert J, Carides GW, Meloche JP, et al. Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial. Can J Clin Pharmacol. 2002 ; 9: 158-164
14. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS). Headache. 2011 ; 51: 1058-1077
15. Serrano D, Manack AN, Reed ML, et al. Cost and predictors of lost productive time in chronic migraine and episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health. 2013 ; 16: 31-38
16. Lucado J, Paez K and Elixhauser A. Headaches in US hospitals and emergency departments, 2008: Statistical brief #111. Healthcare Cost and Utilization Project Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research, 2011.
17. Marco C, Kanitz W, Jolly M. Pain scores amongst emergency department (ED) patients: Comparison by ED diagnosis. J Emerg Med. 2013 ; 44: 46-52
18. Vinson DR, Hurtado TR, Vandenberg JT, et al. Variations among emergency departments in the treatment of benign headache. Ann Emerg Med. 2003 ; 41: 90-97
19. Hurtado TR, Vinson DR, Vandenberg JT. ED treatment of migraine headache: Factors influencing pharmacotherapeutic choices. Headache. 2007 ; 47: 1134-1143
20. Nijjar SS, Pink L, Gordon AS. Examination of migraine management in emergency departments. Pain Res Manag. 2011 ; 16: 183-186
21. Colman I, Rothney A, Wright SC, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology. 2004 ; 62: 1695-1700
22. The International Classification of Headache Disorders. Cephalalgia. 2004 ; 24: 1-160
23. Ad Hoc Committee on Classification of Headache. JAMA 1962; 179: 717-718.
24. McGowan J, Sampson M, Lefebvre C. An evidence based checklist for the peer review of electronic search strategies (PRESS EBC). Evid Based Libr Info Pract. 2010 ; 5: 149-154
25. Lefebvre C, Manheimer E, Glanville J Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. Chichester, UK: John Wiley & Sons Ltd ; 2011: 1-46.
26. National Library of Medicine, 2003. Search strategy used to create the systematic reviews subset on PubMed. http://www.nlm.nih.gov/bsd/pubmed-subsets/sysreviews
27. Lee E, Dobbins M, Decorby K, et al. An optimal search filter for retrieving systematic reviews and meta-analyses. BMC Med Res Methodol. 2012 ; 12: 51-51
28. Higgins JPT and Green S (eds) Cochrane handbook for systematic reviews of interventions, version 5.1.0. Chichester, UK: John Wiley & Sons Ltd, 2011.
29. Harris RD, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med. 2001 ; 20 (3 Suppl). 21-35
30. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 ; 336: 924-926
31. Andrews J, Guyatt GH, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of a recommendation. J Clin Epidemiol. 2013 ; 66: 719-725
32. Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: A multicenter study. Ann Emerg Med. 1995 ; 25: 464-469
33. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991 ; 265: 2831-2835
34. Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia. 1999 ; 19: 581-588
35. Treatment of migraine attacks with sumatriptan: The Subcutaneous Sumatriptan International Study Group. N Engl J Med 1991; 325: 316-321.
36. Mushet GR, Cady RK, Baker CC, et al. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Clin Ther. 1996 ; 18: 687-699
37. Thomson AN, Arthur GP, Bergin PS, et al. Subcutaneous sumatriptan in acute treatment of migraine: A multicentre New Zealand trial. N Z Med J. 1993 ; 106: 171-173
38. Wendt J, Cady R, Singer R, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther. 2006 ; 28: 517-526
39. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005 ; 64: 463-468
40. Kostic MA, Gutierrez FJ, Rieg TS, et al. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010 ; 56: 1-6
41. Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003 ; 21: 173-175
42. Winner P, Ricalde O, La Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996 ; 53: 180-185
43. Friedman BW, Hochberg M, Esses D, et al. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. Headache. 2006 ; 46: 934-941
44. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995 ; 26: 541-546
45. Jones EB, Gonzalez ER, Boggs JG, et al. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994 ; 24: 237-241
46. Friedman BW, Esses D, Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008 ; 52: 399-406
47. Miller MA, Levsky ME, Enslow W, et al. Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache. Am J Emerg Med. 2009 ; 27: 160-164
48. Tanen D, Miller S, French T, et al. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: A prospective, randomized, double-blind trial. Ann Emerg Med. 2003 ; 41: 847-853
49. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: A randomized controlled trial. J Emerg Med. 2002 ; 23: 141-148
50. Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med. 1995 ; 2: 597-602
51. Shrestha M, Singh R, Moreden J, et al. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura: A prospective, randomized, double-blind trial. Arch Intern Med. 1996 ; 156: 1725-1728
52. Tek D, McLellan D, Olshaker J, et al. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990 ; 19: 1083-1087
53. Cete Y, Dora B, Ertan C, et al. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia. 2005 ; 25: 199-204
54. Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: A dose-finding randomized clinical trial. Ann Emerg Med. 2011 ; 57: 475-482
55. Rowat BM, Merrill CF, Davis A, et al. A double-blind comparison of granisetron and placebo for the treatment of acute migraine in the emergency department. Cephalalgia. 1991 ; 11: 207-213
56. Silberstein SD, Young WB, Mendizabal JE, et al. Acute migraine treatment with droperidol. Neurology. 2003 ; 60: 315-321
57. Richman PB, Allegra J, Eskin B, et al. A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. Am J Emerg Med. 2002 ; 20: 39-42
58. Honkaniemi J, Liimatainen S, Rainesalo S, et al. Haloperidol in the acute treatment of migraine: A randomized, double-blind, placebo-controlled study. Headache. 2006 ; 46: 781-787
59. Duarte C, Dunaway F, Turner L, et al. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: A randomized, prospective, double-blind trial. Ann Emerg Med. 1992 ; 21: 1116-1121
60. Larkin GL, Prescott JE. A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine. Ann Emerg Med. 1992 ; 21: 919-924
61. Bigal ME, Bordini CA, Speciali JG. Intramuscular diclofenac in the acute treatment of migraine: A double-blind placebo controlled study [article in Portuguese]. Arqu Neuropsiquitr. 2002 ; 60: 410-415
62. Engindeniz Z, Demircan C, Karli N, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: A prospective, randomised, double-blind study. J Headache Pain. 2005 ; 6: 143-148
63. Jovici? A, Mari? D, Ili? T. Treatment of acute migraine attacks [article in Serbian]. Vojnosanit Pregl. 1995 ; 52: 44-48
64. Krymchantowski AV, Silva MTT. Intravenous lysine clonixinate for the acute treatment of severe migraine attacks: A double-blind, randomized, placebo-controlled study. Curr Ther Res Clin Exp. 2003 ; 64: 505-513
65. Taheraghdam AA, Amiri H, Shojaan H, et al. Intravenous dexamethasone versus morphine in relieving of acute migraine headache. Pak J Biol Sci. 2011 ; 14: 682-687
66. Leinisch E, Evers S, Kaempfe N, et al. Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: A double-blind, placebo-controlled parallel group multicenter study. Pain. 2005 ; 117: 396-400
67. Limmroth V, May A, Diener H. Lysine-ASA in acute migraine attacks. Eur Neurol. 1999 ; 41: 88-93
68. Blanda M, Rench T, Gerson LW, et al. Intranasal lidocaine for the treatment of migraine headache: A randomized, controlled trial. Clin Cornerstone. 2001 ; 4: 65-65
69. Maizels M, Scott B, Cohen Q, et al. Intranasal lidocaine for treatment of migraine. JAMA. 1996 ; 276: 319-321
70. Reutens DC, Fatovich DM, Stewart-Wynne EG, et al. Is intravenous lidocaine clinically effective in acute migraine?. Cephalalgia. 1991 ; 11: 245-247
71. Soleimanpour H, Ghafouri RR, Taheraghdam A, et al. Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: A prospective double blind randomized clinical trial. BMC Neurol. 2012 ; 12: 114-114
72. October 28-31, 2010. Nice, France. J Headache Pain. 2010 ; 11: S92 - S93
73. Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002 ; 22: 345-353
74. Corbo J, Esses D, Bijur PE, et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med. 2001 ; 38: 621-627
75. Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007 ; 69: 2038-2044
76. D'Amico D, Moschiano F, Bussone G. Early treatment of migraine attacks with triptans: A strategy to enhance outcomes and patient satisfaction?. Expert Rev Neurother. 2006 ; 6: 1087-1097
77. MaassenVanDerBrink A, Reekers M, Bax WA, et al. Coronary side effect potential of current and prospective antimigraine drugs. Circulation. 1998 ; 98: 25-30
78. Làinez MJ. The effect of migraine prophylaxis on migraine-related resource use and productivity. CNS Drugs. 2009 ; 23: 727-738
79. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003 ; 43: 171-178
80. Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc. 2001 ; 76: 1093-1101